International Stem Cell Corporation (OTCBB: ISCO), www.internationalstemcell.com,
announces today that its wholly owned subsidiary, Lifeline Skin Care
Inc., has achieved positive results in human safety tests of its
cosmetic products and is moving forward with arrangements with Cosmetic
Enterprises Ltd. for the manufacture of three cosmetic products. These
developments allow Lifeline Skin Care to plan a launch of its cosmetic
product line in the late summer or fall of 2010.
Cosmetic face products developed by Lifeline Skin Care Inc. contain
extracts from human parthenogenetic stem cells (hpSC) combined with a
vitamin complex and other active ingredients. The products utilize a
form of nanotechnology to deliver concentrated active ingredients to
damaged skin. Laboratory tests show that an active "complex" of stem
cell extract has the ability to rejuvenate skin. Also, early human
trials show that these cosmetic products moisturize skin and strongly
indicate the ability to decrease the depth of wrinkles and provide
factors that lead to anti-aging effects.
Lifeline Skin Care is working with Cosmetic Enterprises, Ltd., located
in California, to formulate and package its unique skin care product.
Cosmetic Enterprises is a well-known OTC drug licensed manufacturer with
over 30 years of experience. Lifeline Skin Care's "parthenogenetic stem
cell complex" the product's active ingredient, is made in Lifeline Skin
Care's laboratory in Oceanside, California.
According to Gregory S. Keller, MD, FACS, "These positive safety studies
in human testing are important, especially considering that preliminary
human trial data show that products of the production of International
Stem Cell's parthenogenetic stem cells have significant beneficial
effects on the skin and might also provide long term benefits in
reducing wrinkles and other visible signs of aging. These results are a
significant step forward in making this unique product available to the
public." Dr. Keller was named the 2007 "Specialist of the Year in Facial
Cosmetic Surgery" in Strathmore's "Who's Who".
The results of recent human safety tests show there were no identifiable
signs or symptoms of sensitization (contact allergy). Safety testing is
a series of tests to insure the product does not cause negative
reactions such as irritation to the skin. This completed round of
testing allows Lifeline Skin Care to move forward confidently with its
commercial manufacturing plans.
International Stem Cell Corporation is a pioneer in development of a new
class of stem cells called "human parthenogenetic stem cells" which
avoid critical ethical issues by eliminating the need to use fertilized
embryos and can be immune-matched to large segments of the population.
As of today, ISCO has successfully derived 10 hpSC lines. One of these
lines (hpSC-Hhom-4), carries the most common immune type found across
racial groups within the US population and can be immune-matched to
millions of people.
ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB):
International Stem Cell Corporation is a California-based biotechnology
company focused on therapeutic and research products. ISCO's core
technology, parthenogenesis, results in creation of pluripotent
human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical
issues associated with the use or destruction of viable human embryos.
ISCO scientists have created the first parthenogenic, homozygous stem
cell line that can be a source of therapeutic cells with minimal
immune rejection after transplantation into hundreds of millions of
individuals of differing sexes, ages and racial groups. This offers the
potential to create the first true stem cell bank, UniStemCell™, while
avoiding the ethical issue of using fertilized eggs. ISCO also produces
and markets specialized cells and growth media for therapeutic research
worldwide through its subsidiary Lifeline Cell Technology. More
information is available at ISCO's website, www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications please click on
the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
Statements pertaining to anticipated technological developments and
therapeutic applications, and other opportunities for the company and
its subsidiary, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management constitute forward-looking statements. Any statements that
are not historical fact (including, but not limited to statements that
contain words such as "will," "should," "believes," "plans,"
"anticipates," "expects," "estimates,") should also be considered to be
forward-looking statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, risks inherent in the
development and/or commercialization of potential products, uncertainty
in the results of clinical trials or regulatory approvals, need and
ability to obtain future capital, application of capital resources among
competing uses, and maintenance of intellectual property rights. Actual
results may differ materially from the results anticipated in these
forward-looking statements and as such should be evaluated together with
the many uncertainties that affect the company's business, particularly
those mentioned in the cautionary statements found in the company's
Securities and Exchange Commission filings. The company disclaims any
intent or obligation to update these forward-looking statements.
Key Words: Skin Care, Stem Cells, Biotechnology, Parthenogenesis
International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
Skin Care Inc.
Ruslan Semechkin, PhD, CEO